On November 5–6, 2026, London workplace-health platform Fertifa agreed to acquire Tuune, a London femtech company that makes regulated clinical decision-support software for contraception and menopause. Sky News reported the deal first. FemTech World confirmed it on November 6, and Nelson Advisors' analysis says the price has not been disclosed. FemTech World says Tuune's software assesses more than 70 symptoms alongside a woman's medical history to help clinicians choose a hormonal treatment, rather than defaulting to whatever pill a clinic usually prescribes.

Why It Matters

**Employer benefits are becoming the business model for intimate health.** Contraception side effects and menopause affect far more employees than IVF does, and both bear directly on libido, painful sex and sexual wellbeing. A benefits platform that can recommend a pill or HRT regimen through a clinician and pay for it from the employer's budget reaches users that consumer femtech apps have struggled to monetise. This is the third femtech consolidation deal in a week, after **Cinven–Theramex** ([our coverage](/stories/cinven-acquires-theramex-womens-health)) and Ennogen's purchase of Aspen's European women's-health business. Strategic and PE buyers are rolling up women's-health assets rather than waiting for point solutions to scale alone. **What to watch:** whether Fertifa adds Tuune's contraception engine to the Aviva channel, and whether "personalised" pill selection holds up in clinical evidence. A matching algorithm is implicitly a claim about outcomes, and the deal announcement came without any outcome data on side-effect or discontinuation rates.

The buyer. Fertifa was founded in 2019 as a fertility-benefits provider that helps employers fund IVF and egg freezing. It has since expanded into mental health, neurodiversity, weight management and infant care. Nelson Advisors says it now describes itself as a reproductive, hormonal and sexual health benefits platform covering contraception, menopause, endometriosis, PCOS, STIs and men's sexual health. It is run by Eileen Burbidge, the Passion Capital founding partner and former UK fintech envoy, who has said her own experience of three rounds of IVF, miscarriages and perimenopause drew her to the business. Clients have included Meta, Sony Music, H&M, Lululemon, Space NK and Virgin Group, and Nelson Advisors notes Fertifa is the exclusive provider of Aviva UK's family-planning benefit. Fertifa bought reproductive-health insurer Juniper in July 2025 and raised a £5M seed round in 2023 led by Notion Capital and Triple Point Ventures.

The target. Tuune was co-founded in 2018 by Shardi Nahavandi. Nelson Advisors says she founded it after being misdiagnosed with cancer and repeatedly dismissed by doctors, before working out that her illness came from a hormonal imbalance. Contraception was its first product. It raised $4.6M in October 2021 in a round led by Octopus Ventures to launch in the US. "Tuune has always been about helping women feel understood and receive care that reflects their individual needs," Nahavandi told FemTech World. Burbidge said the deal "takes us another step forward" toward covering "more underserved healthcare needs for employees."

Sources

Update — 2026-11-07

Initial entry — story first created.